Literature DB >> 17249854

A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?

Tracey H Sach1, Richard D Smith, David K Whynes.   

Abstract

Pharmaceutical expenditure represents a large percentage of total healthcare expenditure, and has thus received much attention within the economic evaluation literature. However, although the number of contingent valuation (CV) studies measuring willingness to pay (WTP) in healthcare has increased, little is known about the relative magnitude of values elicited across different interventions, diseases or countries, or the methodological comparability of these values. We address this gap by seeking to establish if it is feasible to use elicited WTP values in resource allocation, illustrated by attempting to compile a 'league table' of WTP values for pharmaceutical interventions. A review database was compiled for CV studies in healthcare published from January 1985 to December 2005. Of 210 studies identified, 40 considered pharmaceutical interventions. Values are presented as mean or median WTP values, adjusted where necessary to pound and $US for 2004/5. Lack of reporting in some instances of either the mean or median, together with heterogenous methods and infrequent reporting of costs, made 'league table' construction difficult. This raises questions about the use of existing studies for resource allocation decisions, despite the fact that most studies were seemingly undertaken for policy objectives. However, four interventions had more than one study, making it possible to compare the values elicited. The values elicited across studies were fairly consistent for two interventions (anti-hypertensive therapy and tumour necrosis factor [TNF]-alpha blockade for rheumatoid arthritis), whereas WTP values for insulin and post-operative emesis therapy were very divergent. No single methodological difference seemed to explain this pattern; however, the more methodological differences between studies the greater the likelihood of divergent values. A checklist, or minimum reporting set of information, is the first step towards improving the consistency of methods, and therefore values, published. In the longer term, a move towards the use of a reference case akin to that used for cost-utility studies would seem important if such studies are to be used for comparative purposes and thereby be relevant to resource allocation decision making.

Entities:  

Mesh:

Year:  2007        PMID: 17249854     DOI: 10.2165/00019053-200725020-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  71 in total

1.  Conjoint analysis. The cost variable: an Achilles' heel?

Authors:  Ulla Slothuus Skjoldborg; Dorte Gyrd-Hansen
Journal:  Health Econ       Date:  2003-06       Impact factor: 3.046

2.  Evidence of range bias in contingent valuation payment scales.

Authors:  David K Whynes; Jane L Wolstenholme; Emma Frew
Journal:  Health Econ       Date:  2004-02       Impact factor: 3.046

3.  Eliciting relative preferences for two methods of colorectal cancer screening.

Authors:  E J Frew; J L Wolstenholme; D K Whynes
Journal:  Eur J Cancer Care (Engl)       Date:  2005-05       Impact factor: 2.520

4.  Willingness to pay for antihypertensive care: evidence from a staff-model HMO.

Authors:  S D Ramsey; S D Sullivan; B M Psaty; D L Patrick
Journal:  Soc Sci Med       Date:  1997-06       Impact factor: 4.634

5.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

6.  Cost-effectiveness league tables: more harm than good?

Authors:  M Drummond; G Torrance; J Mason
Journal:  Soc Sci Med       Date:  1993-07       Impact factor: 4.634

7.  Willingness to pay for inhaled insulin: a contingent valuation approach.

Authors:  Hamid Sadri; Linda D MacKeigan; Lawrence A Leiter; Thomas R Einarson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting.

Authors:  J Tang; B Wang; P F White; M F Watcha; J Qi; R H Wender
Journal:  Anesth Analg       Date:  1998-02       Impact factor: 5.108

9.  Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol.

Authors:  T F Poyner; A P Menday; Z V Williams
Journal:  J Eur Acad Dermatol Venereol       Date:  2000-05       Impact factor: 6.166

10.  Measuring patient preferences by willingness to pay to avoid: the case of acute otitis media.

Authors:  P C Sorum
Journal:  Med Decis Making       Date:  1999 Jan-Mar       Impact factor: 2.583

View more
  5 in total

Review 1.  Conceptualising 'Benefits Beyond Health' in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis.

Authors:  Lidia Engel; Stirling Bryan; David G T Whitehurst
Journal:  Pharmacoeconomics       Date:  2021-08-23       Impact factor: 4.981

2.  Sensitivity to scale of willingness-to-pay within the context of menorrhagia.

Authors:  Sabina Sanghera; Emma Frew; Janesh Kumar Gupta; Joe Kai; Tracy Elizabeth Roberts
Journal:  Health Expect       Date:  2016-02-23       Impact factor: 3.377

3.  Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness-to-Pay Approach.

Authors:  Casper Webers; Ivette Essers; Astrid van Tubergen; Jürgen Braun; Frank Heldmann; Xenofon Baraliakos; Annelies Boonen
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-18       Impact factor: 4.794

4.  Is the value of a life or life-year saved context specific? Further evidence from a discrete choice experiment.

Authors:  Duncan Mortimer; Leonie Segal
Journal:  Cost Eff Resour Alloc       Date:  2008-05-20

5.  Willingness to pay for genetic testing for inherited retinal disease.

Authors:  Sandy Tubeuf; Thomas A Willis; Barbara Potrata; Hilary Grant; Matthew J Allsop; Mushtaq Ahmed; Jenny Hewison; Martin McKibbin
Journal:  Eur J Hum Genet       Date:  2014-06-11       Impact factor: 4.246

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.